If you spend any time in longevity or brain health circles, you have seen it by now. Lithium prevents Alzheimer's. Buy lithium orotate. It is cheap, it is over the counter, and it is sitting right there on the supplement shelf.
The research behind the headline is real and it is interesting. But there is a piece missing from almost every version of this conversation, and it matters if you work with psychedelics or are thinking about it.
What the research actually found
In August 2025, Bruce Yankner's lab at Harvard published a study in Nature. They measured 27 metals in postmortem brain tissue and found lithium significantly lower in the prefrontal cortex of people with mild cognitive impairment and Alzheimer's. Lithium was the only metal significantly altered in the MCI group. Amyloid plaques appear to bind lithium and pull it out of circulation, which starves the surrounding neurons of something they actually need.
Then they went to mice. Cutting brain lithium by roughly half accelerated amyloid deposition, tau accumulation, inflammatory microglial activation, synapse loss, and cognitive decline. Some of that ran through GSK3β. When they supplemented aging mice with lithium orotate, a form selected because it resists binding to amyloid, memory loss reversed. The dose was about one thousandth of what is used to treat bipolar disorder, and mice treated for nearly their whole adult lives showed no evidence of toxicity.
That is a genuinely exciting finding. It is also entirely mouse data on the treatment side.
Yankner has been consistent in every interview: he does not recommend that people start taking lithium orotate. His group is planning human trials. Until those read out, nobody knows the long-term effects in people, and the supplement industry is loose enough that you often cannot be sure what is in the bottle.
The part that is not in the headlines
Here is what I want the people I work with to know.
If you are taking lithium in any form, you should not be taking a classic psychedelic. LSD, psilocybin, mescaline, DMT, 5-MeO-DMT. Not at a full dose, and the low dose question is genuinely unanswered.
In 2021, a Johns Hopkins group published an analysis in Pharmacopsychiatry of online experience reports involving psychedelics taken alongside mood stabilizers. Of 62 reports involving lithium plus a classic psychedelic, 47% involved seizures. Another 18% described bad trips, and 39% involved medical attention. Of 34 lamotrigine reports, zero involved seizures.
Those are self-reported accounts pulled from Erowid, Shroomery, and Reddit. Not a controlled trial. Self-report data skews toward dramatic outcomes, because people write up the night they ended up in the emergency room. But a 47% seizure rate in one group and 0% in a comparable group is not a signal you can wave off.
Does a low dose change anything?
Honest answer: nobody knows, and the little evidence there is does not reassure me.
A 2024 case report in South Dakota Medicine describes a 15-year-old who had three generalized seizures within 30 minutes of taking LSD. No personal or family history of seizures, brain injury, or neurological disorder. She had used LSD monthly on several prior occasions without incident. The seizures began only after she was started on low-dose lithium, and her serum level was still subtherapeutic.
Worth naming the confound. She was also on fluoxetine and bupropion, and bupropion lowers seizure threshold on its own. One case does not establish causation, and the authors say so directly. But it is the closest thing we have to a test of whether a small amount of lithium is safe here, and the answer it gives is no.
Three other things stack on top of that. Nobody has studied lithium orotate microdoses with psychedelics at all, so the data set is empty. The mechanism behind the seizure interaction is not well understood, so there is no way to reason toward a safe threshold from first principles. And lithium acts on intracellular signaling, so skipping the supplement on the morning of a session is not a washout.
What about ketamine?
Different pharmacology, different question. Ketamine is not a classic psychedelic and does not work primarily through 5-HT2A. Lithium and ketamine have actually been given together deliberately in bipolar depression research.
That does not make it a non-issue. It makes it a prescriber conversation rather than a supplement shelf decision. If you are in ketamine-assisted therapy and taking anything with lithium in it, your prescriber needs to know before your next dosing session.
The MAOI blind spot: methylene blue and Syrian rue
Same category of problem, different substance.
Methylene blue has become popular in biohacking circles for mitochondrial and cognitive claims. What most people taking it do not know is that it is a potent reversible MAO-A inhibitor. Ramsay, Dunford, and Gillman confirmed this experimentally in 2007. At clinical intravenous doses it completely inhibits MAO-A and partially inhibits MAO-B. Even doses under 1 mg/kg produce clinically meaningful inhibition. The FDA issued a safety communication in 2011 after reports of serious perioperative events, and the Anesthesia Patient Safety Foundation has a good summary of the case literature, including one death.
In practice: methylene blue combined with an SSRI, SNRI, tricyclic, tramadol, or another MAOI is a serotonin toxicity risk. Standard surgical guidance is roughly two weeks off most SSRIs before methylene blue, and around five weeks for fluoxetine because of its long-acting metabolite.
Syrian rue works on the same enzyme. Its beta-carbolines, harmine and harmaline and tetrahydroharmine, are reversible MAO-A inhibitors. That is exactly why it appears in ayahuasca analogs. It stops DMT from being broken down in the gut.
I want to be precise here, because overstatement in either direction is unhelpful. A 2024 systematic review of ayahuasca adverse events notes that serotonin syndrome from ayahuasca combined with psychiatric medication shows up only in extremely rare case reports, and the authors found no confirmed cases. Reversible MAO-A inhibitors are meaningfully safer than the old irreversible ones. But documented interactions with cocaine and amphetamines include fatalities, and the SSRI combination is the one every reputable retreat screens for.
So the practical rules: do not stack Syrian rue with methylene blue. Do not take either one while on a serotonergic medication. Do not combine either with MDMA or stimulants. And if you are using methylene blue as a nootropic and then sitting a ceremony, you are walking into that ceremony on an MAOI whether or not you think of it that way.
What to do with this
Tell whoever is working with you what you take. Including the 5 mg lithium orotate you ordered online after reading a thread about it.
Read your labels. Lithium and methylene blue turn up inside longevity stacks and nootropic blends, and people genuinely forget they are taking them.
If the Alzheimer's research has you excited, that is fair. It deserves the attention. Follow the clinical trials, talk to your physician, and understand that starting lithium closes the door on classic psychedelics until we know a great deal more than we do now.
Disclose everything during preparation. Not just prescriptions. Supplements, nootropics, herbs, all of it. The interaction that hurts you is almost always the one nobody mentioned.
The lithium finding may end up being one of the most important things to come out of Alzheimer's research in a decade. That is a good reason to watch it closely. It is not a reason to start swallowing it.
This article is educational and is not medical advice. Decisions about lithium, methylene blue, or any supplement belong with your prescribing physician.